ROBINUL FORTE Rx
Generic Name and Formulations:
Glycopyrrolate 2mg; dye-free tabs.
Indications for ROBINUL FORTE:
Adjunct in peptic ulcer.
1–2mg 2–3 times daily; max 8mg daily.
Glaucoma. Unstable cardiovascular status. Asthma. GI or urinary tract obstruction. Paralytic ileus or intestinal atony. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
Reflux esophagitis. Autonomic neuropathy. Impaired hepatic or renal function. Cardiovascular disease. Tachycardia. Hypertension. Hyperthyroidism. High environmental temperature. Diarrhea. Elderly. Debilitated. Pregnancy (Cat.B). Nursing mothers.
Concomitant antacids may inhibit absorption. Cyclopropane anesthetics may cause arrhythmias. Additive anticholinergic effects with other anticholinergics, narcotic analgesics, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics.
Anticholinergic effects (e.g., dry mouth, blurred vision, constipation).
Inj (vials) Single dose 1mL—25
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies